Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$412M |
| 2 |
Advanced Micro Devices
AMD
|
+$294M |
| 3 |
Apple
AAPL
|
+$244M |
| 4 |
Qualcomm
QCOM
|
+$207M |
| 5 |
Pinduoduo
PDD
|
+$180M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$510M |
| 2 |
Uber
UBER
|
+$419M |
| 3 |
Chevron
CVX
|
+$286M |
| 4 |
Meta Platforms (Facebook)
META
|
+$255M |
| 5 |
NVO
Novo Nordisk
NVO
|
+$215M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.64% |
| 2 | Healthcare | 18.28% |
| 3 | Consumer Discretionary | 13.73% |
| 4 | Industrials | 8.66% |
| 5 | Financials | 7.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CARM
3026
DELISTED
Carisma Therapeutics
CARM
| $212K | ﹤0.01% |
139,360
-86,635
| -38% | -$129K |
|
3027
Lipocine
LPCN
$17.5M
| $212K | ﹤0.01% |
25,697
+4,600
| +22% | +$28.8K |
|
|
IOBT
3028
DELISTED
IO Biotech
IOBT
| $212K | ﹤0.01% |
180,800
+13,600
| +8% | +$19K |
|
3029
Marker Therapeutics
MRKR
$18.8M
| $211K | ﹤0.01% |
38,850
+1,600
| +4% | +$6.8K |
|
3030
HF Foods Group
HFFG
$80.2M
| $211K | ﹤0.01% |
70,300
+5,000
| +8% | +$15.9K |
|
|
RGLS
3031
DELISTED
Regulus Therapeutics
RGLS
| $211K | ﹤0.01% |
118,100
+42,600
| +56% | +$98.9K |
|
3032
First Trust Capital Strength ETF
FTCS
$7.91B
| $210K | ﹤0.01% |
2,500
-22,000
| -90% | -$1.84M |
|
3033
Mesa Laboratories
MLAB
$564M
| $208K | ﹤0.01% |
2,400
-13,700
| -85% | -$1.43M |
|
|
HSAI
3034
Hesai Group
HSAI
$2.66B
| $208K | ﹤0.01% |
49,700
+15,200
| +44% | +$72.3K |
|
3035
Equillium
EQ
$139M
| $208K | ﹤0.01% |
300,400
+91,200
| +44% | +$130K |
|
3036
Bolt Biotherapeutics
BOLT
$7.67M
| $208K | ﹤0.01% |
13,837
-12,045
| -47% | -$238K |
|
3037
German American Bancorp
GABC
$1.91B
| $207K | ﹤0.01% |
+5,849
| New | +$191K |
|
3038
PEDEVCO
PED
$144M
| $206K | ﹤0.01% |
11,391
+466
| +4% | +$8.5K |
|
3039
CareCloud
CCLD
$104M
| $206K | ﹤0.01% |
107,200
+21,500
| +25% | +$40.4K |
|
|
DAO
3040
Youdao
DAO
$2.03B
| $205K | ﹤0.01% |
52,300
+3,300
| +7% | +$12.4K |
|
3041
First Trust RBA American Industrial Renaissance ETF
AIRR
$10.1B
| $205K | ﹤0.01% |
+3,000
| New | +$204K |
|
|
ATXS
3042
DELISTED
Astria Therapeutics
ATXS
| $204K | ﹤0.01% |
22,461
-18,939
| -46% | -$185K |
|
|
CTHR
3043
DELISTED
Charles & Colvard Ltd
CTHR
| $204K | ﹤0.01% |
119,069
-19,568
| -14% | -$52.7K |
|
3044
ClearOne Inc
CLRO
$10.9M
| $204K | ﹤0.01% |
20,877
-1,327
| -6% | -$18.6K |
|
|
SSY
3045
DELISTED
SunLink Health Systems
SSY
| $203K | ﹤0.01% |
253,478
-2,900
| -1% | -$1.97K |
|
3046
Priority Technology Holdings
PRTH
$535M
| $202K | ﹤0.01% |
+38,300
| New | +$145K |
|
3047
CEL-SCI Corp
CVM
$20.3M
| $202K | ﹤0.01% |
5,793
+1,333
| +30% | +$56.8K |
|
3048
Direxion Daily Energy Bear 2X ETF
ERY
$39.1M
| $202K | ﹤0.01% |
+8,800
| New | +$198K |
|
3049
State Street SPDR Portfolio S&P 400 Mid Cap ETF
SPMD
$18.2B
| $200K | ﹤0.01% |
3,900
-1,200
| -24% | -$61.9K |
|
3050
Globalstar
GSAT
$10.7B
| $198K | ﹤0.01% |
11,775
+1,346
| +13% | +$24.3K |
|
Similar funds
Renaissance Technologies's Q2 2024 Portfolio in Review
As of Q2 2024, Renaissance Technologies held 4,123 positions worth $59B, down 7.3% from $63.6B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Renaissance Technologies withdrew a net $4.49B in Q2 2024, closing 675 positions and reducing 1,503 holdings. Its most notable exit was Bank of America, an estimated $142M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Renaissance Technologies opened a new position in Broadcom worth $472M.
- Renaissance Technologies's largest Q2 2024 buy was Broadcom: 2,941,150 shares worth $472M.
- Renaissance Technologies added most to Apple in Q2 2024, an estimated $244M increase.
- Renaissance Technologies's biggest Q2 2024 reduction was Amazon, cutting an estimated $510M.
- Renaissance Technologies fully exited Bank of America in Q2 2024, selling an estimated $142M.
- Renaissance Technologies's ten largest holdings make up 12% of its $59B portfolio in Q2 2024.
- Renaissance Technologies opened 463 new positions and closed 675 in Q2 2024.
- Renaissance Technologies's portfolio value fell 7.3% quarter-over-quarter to $59B.
Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.